The 6 most recent market catalysts affecting $GNDX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 18, 2026
Corporate Catalyst
Neutral
Impact 75
GeneDx Announces Leadership Transition
GeneDx Holdings Corp. has appointed Everett Cunningham as its new Chief Executive Officer, effective November 18, 2026. This is a significant leadership change, as Cunningham is de…
Nov 13, 2026
Corporate Catalyst
Bearish
Impact 75
Analysts Adjust Estimates and Price Targets for GeneDx Holdings Following Quarterly Results
GeneDx Holdings reported quarterly revenue that met analyst expectations, but its loss per share exceeded predictions by 7.3%. This larger-than-expected loss has prompted analysts …
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 92
GeneDx Holdings Corp. Reports Q3 2026 Financial Results
GeneDx Holdings Corp. announced Q3 2026 results that significantly exceeded market expectations, particularly on the adjusted EPS front ($0.28 vs. $0.07 estimate). Revenue also sli…
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 55
GeneDx Partners With Beren Therapeutics To Launch The NPC GenomeComplete Sponsored Testing Program For Niemann-Pick Disease Type C
GeneDx is collaborating with Beren Therapeutics to offer a sponsored, no-cost genome sequencing program for Niemann-Pick Disease Type C (NPC). This program aims to address the sign…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 75
GeneDx Holdings shares are trading higher after the company reported better-than-expected Q2 financial results. Also, Canaccord Genuity raised its price target from $75 to $90.
This headline indicates a strong positive corporate catalyst for GeneDx Holdings. Better-than-expected financial results demonstrate operational strength and potentially increased …
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 75
GeneDx Hldgs Q2 Adj. EPS $(0.28) Misses $(0.19) Estimate, Sales $114.440M Beat $111.011M Estimate
The headline presents a classic mixed bag for GeneDx Holdings (GNDX). While the sales beat indicates strong demand for their genetic testing services, the significant EPS miss sugg…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.